Clinical characteristics and first-line treatment among patients diagnosed with MCL at age <70 years in Sweden between 2000 and 2014 (N = 620) by HD-ASCT or not within 12 months of diagnosis
| Variable . | Patients not treated with HD-ASCT<12 m . | Patients treated with HD-ASCT<12 m . | P value . | All patients, N (column %) <70 y . |
|---|---|---|---|---|
| Overall, N | 373 | 247 | 620 (100) | |
| Stage | ||||
| Ann Arbor I, n (%) | 41 (11.2) | 4 (1.6) | <.001 | 45 (7.3) |
| Ann Arbor II, n (%) | 33 (9) | 17 (6.9) | 50 (8.2) | |
| Ann Arbor III, n (%) | 45 (12.3) | 36 (14.6) | 81 (13.2) | |
| Ann Arbor IV, n (%) | 248 (67.6) | 189 (76.8) | 437 (71.3) | |
| Missing, n | 6 | 1 | 7 | |
| MCL-specific international prognostic index | ||||
| Low risk (<5.7), n (%) | 80 (28.9) | 72 (36.7) | .126 | 152 (32.1) |
| Intermediate risk (5.7-6.1), n (%) | 102 (36.8) | 71 (36.2) | 173 (36.6) | |
| High risk (>6.1), n (%) | 95 (34.3) | 53 (27) | 148 (31.3) | |
| Missing, n | 96 | 51 | 147 | |
| Treatment | ||||
| NLG-MCL2 protocol, n (%)∗ | 50 (17.5) | 186 (94.4) | <.001 | 236 (48.9) |
| R-CHOP alternating with R-cytarabine or R-cytarabine single, n (%)† | 43 (15) | 8 (4.1) | 51 (10.6) | |
| R-CHOP, n (%) | 74 (25.9) | 3 (1.5) | 77 (15.9) | |
| Chlorambucil, n (%) | 27 (9.4) | 0 (0) | 27 (5.6) | |
| R-fludarabine or cyclophosphamide n (%)† | 6 (2.1) | 0 (0) | 6 (1.2) | |
| R-bendamustine, n (%)† | 21 (7.3) | 0 (0) | 21 (4.4) | |
| Wait and watch, n (%) | 21 (7.3) | 0 (0) | 21 (4.4) | |
| Radiotherapy only, n (%) | 34 (11.9) | 0 (0) | 34 (7) | |
| Other treatment, n (%)‡ | 10 (3.5) | 0 (0) | 10 (2.1) | |
| Missing, n | 87 | 50 | 137 |
| Variable . | Patients not treated with HD-ASCT<12 m . | Patients treated with HD-ASCT<12 m . | P value . | All patients, N (column %) <70 y . |
|---|---|---|---|---|
| Overall, N | 373 | 247 | 620 (100) | |
| Stage | ||||
| Ann Arbor I, n (%) | 41 (11.2) | 4 (1.6) | <.001 | 45 (7.3) |
| Ann Arbor II, n (%) | 33 (9) | 17 (6.9) | 50 (8.2) | |
| Ann Arbor III, n (%) | 45 (12.3) | 36 (14.6) | 81 (13.2) | |
| Ann Arbor IV, n (%) | 248 (67.6) | 189 (76.8) | 437 (71.3) | |
| Missing, n | 6 | 1 | 7 | |
| MCL-specific international prognostic index | ||||
| Low risk (<5.7), n (%) | 80 (28.9) | 72 (36.7) | .126 | 152 (32.1) |
| Intermediate risk (5.7-6.1), n (%) | 102 (36.8) | 71 (36.2) | 173 (36.6) | |
| High risk (>6.1), n (%) | 95 (34.3) | 53 (27) | 148 (31.3) | |
| Missing, n | 96 | 51 | 147 | |
| Treatment | ||||
| NLG-MCL2 protocol, n (%)∗ | 50 (17.5) | 186 (94.4) | <.001 | 236 (48.9) |
| R-CHOP alternating with R-cytarabine or R-cytarabine single, n (%)† | 43 (15) | 8 (4.1) | 51 (10.6) | |
| R-CHOP, n (%) | 74 (25.9) | 3 (1.5) | 77 (15.9) | |
| Chlorambucil, n (%) | 27 (9.4) | 0 (0) | 27 (5.6) | |
| R-fludarabine or cyclophosphamide n (%)† | 6 (2.1) | 0 (0) | 6 (1.2) | |
| R-bendamustine, n (%)† | 21 (7.3) | 0 (0) | 21 (4.4) | |
| Wait and watch, n (%) | 21 (7.3) | 0 (0) | 21 (4.4) | |
| Radiotherapy only, n (%) | 34 (11.9) | 0 (0) | 34 (7) | |
| Other treatment, n (%)‡ | 10 (3.5) | 0 (0) | 10 (2.1) | |
| Missing, n | 87 | 50 | 137 |
Because of rounding, not all percentages add up to 100.
Nordic lymphoma group MCL2 protocol containing R-CHOP and high-dose cytarabine.
Number of patients with confirmed rituximab: 37 in the CHOP or cytarabine group, 42 in the CHOP group, 1 in the fludarabine or cyclophosphamide group, and 11 in the bendamustine group.
Either R-bendamustine alternating with R-cytarabine or unspecified chemotherapy; detailed frequencies not shown in subgroups owing to cell count <4.